Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

811
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
811
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

492
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
492
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

653
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
653
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

481
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Skin involvement in the catastrophic antiphospholipid syndrome: A review from CAPS registry.

Lupus·2026
Same author

Serological autoimmune profile of systemic lupus erythematosus in deep and non-deep endometriosis patients.

Journal of reproductive immunology·2023
Same author

Patients with laboratory criteria of anti-phospholipid syndrome and 'non-criteria' manifestations: a multicenter cohort.

Scandinavian journal of rheumatology·2022
Same author

European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance.

Annals of the rheumatic diseases·2021
Same author

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.

Annals of the rheumatic diseases·2020
Same author

COVID-19 and Behçet's disease: clinical case series.

Annals of the rheumatic diseases·2020

Related Experiment Video

Updated: Apr 23, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K

Catastrophic antiphospholipid syndrome: task force report summary.

R Cervera1, I Rodríguez-Pintó2,

  • 1Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain rcervera@clinic.cat.

Lupus
|September 18, 2014
PubMed
Summary
This summary is machine-generated.

Catastrophic Antiphospholipid Syndrome (CAPS) is a rare, severe condition. This report summarizes current knowledge on CAPS, covering its causes, symptoms, diagnosis, and treatments for better patient outcomes.

Keywords:
Antiphospholipid syndromeanticardiolipin antibodiesantiphospholipid antibodieslupus anticoagulant

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

473

Related Experiment Videos

Last Updated: Apr 23, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

473

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Catastrophic Antiphospholipid Syndrome (CAPS) represents a life-threatening variant of Antiphospholipid Syndrome.
  • Understanding CAPS is crucial due to its high morbidity and mortality rates.

Purpose of the Study:

  • To consolidate and present the collective knowledge on Catastrophic Antiphospholipid Syndrome (CAPS).
  • To provide a comprehensive overview of pathogenesis, clinical and laboratory features, diagnosis, classification, precipitating factors, and treatment of CAPS.

Main Methods:

  • Systematic review and consensus-building by a dedicated Task Force.
  • Analysis of existing literature and clinical data pertaining to CAPS.

Main Results:

  • Detailed characterization of CAPS pathogenesis and its triggers.
  • Established criteria for diagnosis and classification of CAPS.
  • Outlined current therapeutic strategies and management guidelines for CAPS.

Conclusions:

  • The Task Force report provides a unified perspective on CAPS.
  • Enhanced understanding and standardized approaches are expected to improve CAPS patient care and outcomes.